NASDAQ: PULM
Pulmatrix Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their PULM stock forecasts and price targets.

Forecast return on equity

Is PULM forecast to generate an efficient return?

Company
-176.31%
Industry
74.84%
Market
260.67%
PULM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PULM forecast to generate an efficient return on assets?

Company
-167.5%
Industry
25.73%
PULM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PULM earnings per share forecast

What is PULM's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$5.05
Avg 2 year Forecast
-$2.28

PULM revenue forecast

What is PULM's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$7.1M+238,066.67%
Avg 2 year Forecast
$16.8M+559,300%
PULM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PULM revenue growth forecast

How is PULM forecast to perform vs Biotechnology companies and vs the US market?

Company
238,066.67%
Industry
9,228.5%
Market
1,339.67%
PULM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PULM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PULM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PULM$4.84N/AN/A
BLRX$3.72$19.00+410.75%Strong Buy
CMMB$3.25$25.00+669.23%Buy
ADAP$0.07$0.65+904.62%Sell
HOTH$1.37$5.00+264.96%Strong Buy

Pulmatrix Stock Forecast FAQ

What is PULM's earnings growth forecast for 2025-2026?

(NASDAQ: PULM) Pulmatrix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 129.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,785.55%.

Pulmatrix's earnings in 2025 is -$6,220,000.On average, 3 Wall Street analysts forecast PULM's earnings for 2025 to be -$18,440,387, with the lowest PULM earnings forecast at -$17,717,235, and the highest PULM earnings forecast at -$18,982,751.

In 2026, PULM is forecast to generate -$8,344,741 in earnings, with the lowest earnings forecast at -$8,017,496 and the highest earnings forecast at -$8,590,174.

If you're new to stock investing, here's how to buy Pulmatrix stock.

What is PULM's revenue growth forecast for 2025-2026?

(NASDAQ: PULM) Pulmatrix's forecast annual revenue growth rate of 238,066.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,228.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 1,339.67%.

Pulmatrix's revenue in 2025 is $3,000.On average, 3 Wall Street analysts forecast PULM's revenue for 2025 to be $26,095,576, with the lowest PULM revenue forecast at $25,072,937, and the highest PULM revenue forecast at $26,862,556.

In 2026, PULM is forecast to generate $61,292,647 in revenue, with the lowest revenue forecast at $58,889,443 and the highest revenue forecast at $63,096,876.

What is PULM's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: PULM) forecast ROA is -167.5%, which is lower than the forecast US Biotechnology industry average of 25.73%.

What is PULM's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: PULM) Pulmatrix's current Earnings Per Share (EPS) is -$1.71. On average, analysts forecast that PULM's EPS will be -$5.05 for 2025, with the lowest EPS forecast at -$4.85, and the highest EPS forecast at -$5.20. In 2026, PULM's EPS is forecast to hit -$2.28 (min: -$2.20, max: -$2.35).

What is PULM's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: PULM) forecast ROE is -176.31%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.